SOURCE: PharmaRoth Labs, Inc.

June 14, 2016 08:30 ET

PharmaRoth Labs Announces New Clinical Trials for Sucanon in Mexico

LAS VEGAS, NV--(Marketwired - Jun 14, 2016) - PharmaRoth Labs, Inc. (OTC PINK: ROTH), the exclusive producer, marketer, and distributor of Sucanon®, an oral Type-II Diabetes treatment, today announced that it has started new clinical trials in Mexico City, Mexico. The test is for recently diagnosed Type-II diabetic patients and will cover over 200 participants for a duration of 12 weeks. The trial will be conducted at the Centro Medico ABC in Mexico City.

"We are very excited to start a new clinical trial for Sucanon® to address the recent diagnosed Type-II diabetic patient segment. In Mexico the latest figures from the International Diabetes Federation show prevalence of this disease has increased by over 30%., and an estimated increase of 50% during following 20 years. This trial is being conducted to test the effects of Sucanon® active ingredients in Insulin Resistance in combination with other medicines. We are very confident that Sucanon® will, as it has in the past, show excellent results," commented Luis Lopez, CEO of PharmaRoth.

Mr. Lopez further states: "We are also very pleased that this trial is being conducted at the Centro Medico ABC in Mexico City. It is a very prestigious institution and a testament to our Advisor Dr. Rojas, who will be one of the leaders of the trial. We look forward to announcing the results at the conclusion of the trial," Mr. Lopez concluded.

For more information regarding Centro Medico Hospital, please visit: http://www.abchospital.com

About Sucanon®
Sucanon® is a diabetes oral treatment containing natural ingredient. In certain countries, it is one of only three approved drugs in the multi-billion dollar market for a class of diabetic medications called "insulin sensitizers." Pre-clinical and clinical studies have shown that Sucanon® and other insulin sensitizers lower a patient's blood sugar by increasing the muscle, fat and liver's sensitivity to the body's own naturally produced insulin. Sucanon® is currently approved as an OTC treatment for Type-II diabetes by regulatory authorities in Mexico, and Canada and is distributed thought Mexico at various pharmacy chains.

For more information regarding Sucanon®, please visit www.pharmaroth.com

About PharmaRoth
PharmaRoth Labs, Inc. (OTC Pink: ROTH) is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon®, an oral treatment for Type-II diabetes. Sucanon® is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver's sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars. PharmaRoth's strategy is to increase awareness, acceptance, and distribution of Sucanon® globally.

Forward Looking Statements: Statements in this document contain certain forward-looking Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of PharmaRoth Labs, Inc. to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. PharmaRoth Labs, Inc. assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors. There may be other factors not mentioned above that may cause actual results to differ materially from those projected in any forward-looking statement. We assume no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by applicable securities laws.

Contact Information

  • For Investor Relations contact:
    Michael Irving
    Paramount Advisors, LLC
    (407) 878-5462
    mike@parvise.com